비소세포폐암에서 DR5 TRAIL 수용체와 p53에 관한 면역조직화학적 분석

Immunohistochemical Analysis for the Expression of DR5 TRAIL Receptor and p53 in Non-small Cell Lung Cancer

  • 이계영 (건국대학교 의과대학 내과학교실) ;
  • 이정현 (건국대학교 의과대학 내과학교실) ;
  • 김순종 (건국대학교 의과대학 내과학교실) ;
  • 유광하 (건국대학교 의과대학 내과학교실)
  • Lee, Kye-Young (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Lee, Jung-Hyun (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Kim, Sun-Jong (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Yoo, Kwang-Ha (Department of Internal Medicine, Konkuk University School of Medicine)
  • 투고 : 2008.02.11
  • 심사 : 2008.04.10
  • 발행 : 2008.04.30

초록

연구배경: TRAIL 은 death 수용체(DR4, DR5)와 decoy 수용체(DcR1, DcR2)라는 독특한 수용체 시스템 덕분에 정상세포는 보호하고 종양선택적 살상능을 가진 유망한 항암제로 주목받고 있다. DR5 TRAIL 수용체는 wild-type p53 세포에서 DNA 손상항암제인 doxorubicine에 의해 발현 유도되는 p53-조절 death 수용체 유전자로 처음에 발견되었다. 폐암 조직에서 이러한 DR5와 p53 발현에 관연 연구 보고는 많지 않다. 본 연구에서 비소세포폐암 조직에서 면역조직화학적 방법을 이용하여 DR5 발현과 p53과의 상관관계를 중심으로 분석하였다. 방법: Avidin-biotinylated horseradish peroxidase complex를 이용하여 89예의 수술적 절제된 비소세포폐암 포르말린 고정조직에서 면역조직화학적 염색을 시행하였다. 1차 항체로는 anti-DR5 polyclonal antibody (Pro Sci Inc., Poway, CA)와 anti-p53 monoclonal antibody (DO-7, Novocastra, Inc, Manhasset, NY)를 이용하였다. DR5 발현에 대한 면역조직화학적 판정은 면역염색의 범위와 강도를 합산하여 다음과 같이 판정하였다; 0, non-staining; 1+, weak and diffuse(>50%) or focal (<50%) or moderate and focal; 2+, strong and focal or moderate and diffuse ; 3+, strong and diffuse. 2+ 이상을 고발현(high expression)으로 분류하였다. p53 발현 정도에 따른 p53 wild type과 mutant type의 구분은 3+의 강양성인 경우를 mutant type으로 판정하였고, 나머지 0, 1+, 2+ 발현은 wild type p53으로 판정하였다. 결과: 주변 정상폐조직에서의 DR5발현은 기관지점막에서 89%의 고발현율을 보였으나, type I, II 폐상피세포, 림프구, 평활근세포 등의 정상 세포에서는 거의 발현되지 않았다. 폐암 조직에서 DR5 고발현율은 편평상피암에서 28% (15/53), 선암에서 47% (15/32), 대세포암에서 50% (2/4)의 빈도를 보여 전반적으로 36%의 고발현율을 보였다. DR5 고발현율은 임상병기, 생존기간 등 임상 지표와 유의한 상관관계를 보여주지 못하였지만 p53 발현과는 유의한 역상관관계를 보여주었다. 결론: 비소세포폐암 조직에서 면역조직화학적 분석을 통하여 DR5 발현이 기관지점막을 제외하고는 종양 선택적임을 확인하였고 p53 발현과 유의한 역상관관계가 있음을 확인하였다. 이는 DR5가 p53 조절 유전자임을 in vivo에서 확인한 유력한 증거일 수 있다고 생각된다.

Background: TRAIL is a promising anticancer agent which induces selective tumor cell death due to a unique receptor system that includes death receptors and decoy receptors. DR5 TRAIL receptor is an originally identified p53-regulated death receptor gene that was induced, by doxorubicine, only in cells with a wild-type p53 status. We investigated that focused on the correlation between the DR5 and p53 expressions in non-small cell lung cancer (NSCLC). Methods: Immunohistochemical analysis, with using avidin-biotinylated horseradish peroxidase complex, was carried out in 89 surgically resected NSCLC formalin-fixed paraffin-embedded tissue sections. As primary antibodies, we used anti-DR5 polyclonal antibody and anti-p53 monoclonal antibody. A negative control was processed with each slide. The positive tumor cells were quantified twice and these values were expressed as percentage of the total number of tumor cells, and the intensity of immunostaining was expressed. The analysis of the DR5 expression was done separately in tumor area and in a nearby region of normal tissue. Results: The DR5 expression was high in the bronchial epithelium (89% of cases) but this was almost absent in type I & II pneumocytes, lymphocytes and smooth muscle cells. High DR5 expression rate in tumor was seen in 28% (15/53) of squamous cell carcinomas, in 47% (15/32) of adenocarcinomas and, in 50% (2/4) of large cell carcinomas. The DR5 expression did not show any statistical significance relationship with the T stage, N stage, or survival. However, the DR5 expression showed significant inverse correlation with the p53 expression. (p< 0.01). Conclusion: We demonstrated that the DR5 expression in NSCLC via immunohistochemical analysis is relatively tumor-specific except for that in the normal bronchial epithelium and it is significantly dependent on the p53 status. This might be in vivo evidence for the significance of the DR5 gene as a p53 downstream gene.

키워드

참고문헌

  1. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8 https://doi.org/10.1126/science.281.5381.1305
  2. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104: 155-62 https://doi.org/10.1172/JCI6926
  3. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001;7: 383-5 https://doi.org/10.1038/86397
  4. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63 https://doi.org/10.1038/5517
  5. Wu GS, Burns TF, McDonald ER 3rd, Jiang W, Meng R, Krantz ID, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141-3 https://doi.org/10.1038/ng1097-141
  6. Kim K, Takimoto R, Dicker DT, Chen Y, Gazitt Y, El-Deiry WS. Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. Int J Oncol 2001;18:241-7
  7. Jang SH, Seol JY, Kim CH, Yoo CG, Kim YW, Han SK, et al. Additive effect of TRAIL and p53 gene transfer on apoptosis of human lung cancer cell lines. Int J Mol Med 2004;13:181-6
  8. Bremer E, van Dam G, Kroesen BJ, Leij L, Helfrich W. Targeted induction of apoptosis cancer therapy: current progress and prospects. Trends Mol Med 2006;12: 382-93 https://doi.org/10.1016/j.molmed.2006.06.002
  9. Gajewski TF. On the TRAIL toward death receptorbased cancer therapeutics. J Clin Oncol 2007;25:1305-7 https://doi.org/10.1200/JCO.2006.09.9804
  10. Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007;25:1390-5 https://doi.org/10.1200/JCO.2006.08.8898
  11. Cretney E, Uldrich AP, Berzins SP, Strasser A, Godfrey DI, Smyth MJ. Normal thymocyte negative selection in TRAIL-deficient mice. J Exp Med 2003;198:491-6 https://doi.org/10.1084/jem.20030634
  12. Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res 1999;59:5683-6
  13. Wu WG, Soria JC, Wang L, Kemp BL, Mao L. TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer. Anticancer Res 2000;20: 4525-9
  14. Spierings DC, de Vries EG, Timens W, Groen HJ, Boezen HM, de Jong S. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 2003;9:3397-405
  15. Mitsiades N, Poulaki V, Mitsiades C, Tsokos M. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res 2001;61:2704-12
  16. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999;59:2747-53
  17. Zhang XD, Franco AV, Nguyen T, Gray CP, Hersey P. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 2000;164:3961-70 https://doi.org/10.4049/jimmunol.164.8.3961
  18. El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ 2001;8:1066-75 https://doi.org/10.1038/sj.cdd.4400943
  19. Oren M. Decision making by p53: life, death, and cancer. Cell Death Differ 2003;10:431-42 https://doi.org/10.1038/sj.cdd.4401183
  20. Sheikh MS, Fornace AJ Jr. Death and decoy receptors and p53-mediated apoptosis. Leukemia 2000;14:1509- 13 https://doi.org/10.1038/sj.leu.2401865
  21. Liu X, Yue P, Khuri FR, Sun SY. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res 2005;65:9169-75 https://doi.org/10.1158/0008-5472.CAN-05-0939